Inhibitory effect of long-circulating miR-135a-containing cationic immunoliposomes modified by anti-EGFR on gallbladder carcinoma cells

doi:10.3877/cma.j.issn.2095-3232.2018.05.016

Abstract

Abstract:

Objective

To construct the long-circulating cationic immunoliposomes modified by anti-epidermal growth factor receptor (EGFR) (anti-EGFR-CILs), to evaluate the physicochemical properties and targeting ability, and explore its effect of transloading miR-135a on the invasion, metastasis and apoptosis of gallbladder carcinoma (GBC) cells.

Methods

The immunoliposomes loaded with miR-135a were prepared by film-dispersion and hydration-sonication methods. The morphology, particle size distribution, ζ-potential, drug entrapment efficiency, drug loading efficiency and transfection rate were detected. The effect of miR-135a on the invasion, metastasis and apoptosis of GBC cells were evaluated by Transwell assay and Annexin V/PI staining. The absorbance values (A) among different groups were compared by single factor analysis of variance and LSD-t test.

Results

anti-EGFR-CILs possessed excellent physicochemical properties and targeting ability. The drug entrapment efficiency and drug loading efficiency of anti-EGFR-CILs were 73.91% and 1.43%. The in vitro cell transfection rate of 86.5%. Transwell assay demonstrated that anti-EGFR-CIL-miR-135a exerted significantly higher inhibitory effect upon GBC cells compared with anti-EGFR-CIL-pWPXL (LSD-t=37.62, P<0.05). Cellular apoptosis assay revealed that miR-135a promoted the apoptosis of GBC cells and the apoptosis rate was approximately 21%.

Conclusions

anti-EGFR-CILs is a highly targeted and efficient gene vector. anti-EGFR-CIL-miR-135a is a potential and alternative therapy for gallbladder cancer.

Key words: Gallbladder neoplasms, Receptor, epidermal growth factor, Immunity, Liposomes, miR-135a, Genes

Guanghua Yang, Jianxun Zhang, Baobing Yin. Inhibitory effect of long-circulating miR-135a-containing cationic immunoliposomes modified by anti-EGFR on gallbladder carcinoma cells[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2018, 07(05): 414-419.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2018.05.016

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2018/V07/I05/414

Figures/Tables 4

References 20

[1]	Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome[J]. Clin Epidemiol, 2014(6):99-109.
[2]	Shen HX, Song HW, Xu XJ, et al. Clinical epidemiological survey of gallbladder carcinoma in northwestern China, 2009-2013: 2379 cases in 17 centers[J]. Chronic Dis Transl Med, 2017, 3(1):60-66.
[3]	Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges[J]. Nat Rev Drug Discov, 2010, 9(10):775-789.
[4]	Chandra V, Kim JJ, Mittal B, et al. MicroRNA aberrations: an emerging field for gallbladder cancer management[J]. World J Gastroenterol, 2016, 22(5):1787-1799.
[5]	Zhou H, Guo W, Zhao Y, et al. MicroRNA-135a acts as a putative tumor suppressor by directly targeting very low density lipoprotein receptor in human gallbladder cancer[J]. Cancer Sci, 2014, 105(8):956-965.
[6]	Pais-Costa SR, Farah JF, Artigiani-Neto R, et al. Evaluation of P53, E-cadherin, Cox-2, and EGFR protein imunnoexpression on prognostic of resected gallbladder carcinoma[J]. Arq Bras Cir Dig, 2014, 27(2):126-132.
[7]	Kirpotin DB, Noble CO, Hayes ME, et al. Building and characterizing antibody-targeted lipidic nanotherapeutics[J]. Methods Enzymol, 2012(502):139-166.
[8]	Juang V, Lee HP, Lin AM, et al. Cationic PEGylated liposomes incorporating an antimicrobial peptide tilapia hepcidin 2-3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells[J]. Int J Nanomedicine, 2016(11):6047-6064.
[9]	Ramamoorth M, Narvekar A. Non viral vectors in gene therapy-an overview[J]. J Clin Diagn Res, 2015, 9(1):GE1-6.
[10]	Sanna V, Pala N, Sechi M. Targeted therapy using nanotechnology: focus on cancer[J]. Int J Nanomedicine, 2014(9):467-483.
[11]	Adiseshaiah PP, Hall JB, McNeil SE. Nanomaterial standards for efficacy and toxicity assessment[J]. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2010, 2(1):99-112.
[12]	Goodwin T, Huang L. Nonviral vectors: we have come a long way[J]. Adv Genet, 2014(88):1-12.
[13]	Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications[J]. Nano Lett, 2010, 10(9):3223-3230.
[14]	Yin H, Kanasty RL, Eltoukhy AA, et al. Non-viral vectors for gene-based therapy[J]. Nat Rev Genet, 2014, 15(8):541-555.
[15]	Mortensen JH, Jeppesen M, Pilgaard L, et al. Targeted antiepidermal growth factor receptor (cetuximab) immunoliposomes enhance cellular uptake in vitro and exhibit increased accumulation in an intracranial model of glioblastoma multiforme[J]. J Drug Deliv, 2013:209205.
[16]	Kuai JH, Wang Q, Zhang AJ, et al. Epidermal growth factor receptor-targeted immune magnetic liposomes capture circulating colorectal tumor cells efficiently[J]. World J Gastroenterol, 2018, 24(3):351-359.
[17]	Yamada Y, Hidaka H, Seki N, et al. Tumor-suppressive microRNA-135a inhibits cancer cell proliferation by targeting the c-MYC oncogene in renal cell carcinoma[J]. Cancer Sci, 2013, 104(3):304-312.
[18]	Dang Z, Xu WH, Lu P, et al. MicroRNA-135a inhibits cell proliferation by targeting Bmi1 in pancreatic ductal adenocarcinoma[J]. Int J Biol Sci, 2014, 10(7):733-745.
[19]	Shin JY, Kim YI, Cho SJ, et al. MicroRNA 135a suppresses lymph node metastasis through down-regulation of ROCK1 in early gastric cancer[J]. PLoS One, 2014, 9(1):e85205.
[20]	Tang W, Jiang Y, Mu X, et al. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression[J]. Cell Signal, 2014, 26(7):1420-1426.

Please choose a citation manager

Content to export